The pricing barrier: cost-effectiveness of Glofitamab for relapsed/refractory DLBCL in China beyond threshold and value-based pricing strategy considerations
Although Glofit-GemOx offers significant survival benefits, it is not cost-effective in China at current prices. Price reductions or insurance coverage could improve accessibility, supporting the need for value-based pricing strategies.
Authors
- Shen Lin (ORCID: https://orcid.org/0000-0002-5100-2597)
- Xiaoyin Huang (ORCID: https://orcid.org/0009-0008-4760-7164)
- Xiuhua Weng
- Xiangzhen Wang
- Shaohong Luo
- Lijing Yang
- Xiongwei Xu
Institutions
- Fujian Medical University (CN)
- Mengchao Hepatobiliary Hospital (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- Expert Review of Anticancer Therapy
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1080/14737140.2026.2630025
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00